Current price is less than the intrinsic value
Stock has been generating better return on equity than bank FD
Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Pro Only
Pro Only
Pro Only
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Customise key metrics, see detailed forecasts, download stock data and more
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
18 hours ago•Moneycontrol
1 day ago•Moneycontrol
1 day ago•Business Standard
Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 09-May-2022 titled Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064% | Download
Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 09-May-2022 titled Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064% | Download
Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 20-May-2022 titled Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP, 500 mg | Download
Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 20-May-2022 titled Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP, 500 mg | Download
Final • Div/Share: ₹ 2.5
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Current price is less than the intrinsic value